<DOC>
	<DOCNO>NCT01583439</DOCNO>
	<brief_summary>The goal `` Mochudi Prevention Project '' reduce number new HIV infection village Mochudi , Botswana promote comprehensive package intervention proven effective prevent spread HIV . This antiretroviral treatment ( ART ) clinical study nest within Mochudi Prevention Project , conduct north-east segment ( NES ) village Mochudi . The ART intervention component Mochudi Project design determine uptake , adherence , feasibility 3-drug combination ART component package transmission prevention strategy . The hypothesis 1 ) ART ( 3 antiretrovirals two class drug ) among participant CD4 ≥ 250 cells/mm3 VL ≥ 50,000 cp/mL acceptable safe 2 ) Eighty percent eligible participant agree start 3-drug ART .</brief_summary>
	<brief_title>The Mochudi Prevention Project ART Protocol</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 infection CD4 cell count ≥ 250 cells/mm3 HIV1 RNA ≥ 50,000 cp/mL No AIDSdefining illness illness would cause volunteer eligible ART Botswana National Program ( volunteer refer National Program treatment ) Age 16 64 year Botswana citizen Resident northeast segment Mochudi The following laboratory value obtain within 60 day prior study enrollment : Absolute neutrophil count ( ANC ) ≥ 500 cells/mm3 . Hemoglobin ≥ 7.0 g/dL . AST ( SGOT ) , ALT ( SGPT ) , bilirubin ≤ 5 X ULN . Note : estimate creatinine clearance ( CockgroftGault equation ) &lt; 60 mL/min , TDF/FTC substitute ZDV/3TC Ability swallow oral medication . Ability willingness participant give inform consent ( case participant &lt; 18 year age , ability willingness provide assent ; parent/guardian provide consent ) . Not currently involuntarily incarcerate . Karnofsky performance score ≥ 70 time study enrollment . If participate sexual activity could lead pregnancy reproductive potential , female participant must use two reliable method contraception simultaneously , one must barrier method , receive protocolspecified medication , 12 week stop medication . For participant &lt; 18 year age : Weight 40kg Receipt time prior study enrollment &gt; 7 day cumulative treatment ARV combination ARVs ( except ARVs take length time pregnancy prevention mothertochild transmission ( pMTCT ) ARVs take occupational exposure ) . Current receipt 3drug ART pMTCT Allergy/sensitivity study drug formulation . Acute therapy serious medical illness , opinion site investigator , within 14 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Sexually Transmitted Diseases , Viral</keyword>
	<keyword>Immunologic Deficiency Syndromes</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>